Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $8.2 million, or $0.21 per share, compared with a net loss of $17.7 million, or $0.46 per share, for the same period in 2008. For the nine months ended September 30, 2009, the Company reported a net loss of $43.1 million, or $1.11 per share, as compared to $59.8 million, or $1.56 per share, for the same period last year.

Revenues for the third quarter of 2009 were $0.7 million, compared with $0.8 million for the same period last year. Revenues for the nine months ended September 30, 2009 were $2.2 million, compared with $3.2 million for the same period in 2008. The decrease in revenues is primarily due to milestones recognized in 2008 under our collaboration agreement with GlaxoSmithKline related to the clinical advancements of our CRF program. During both nine month periods ending September 30, 2009 and 2008, we recognized $2.2 million in revenue under our collaboration agreement for indiplon with Dainippon Sumitomo Pharma Co. Ltd. from amortization of up-front licensing fees.

Research and development expenses decreased to $7.4 million during the third quarter of 2009 compared with $13.0 million for the same period in 2008. For the nine months ended September 30, 2009, research and development expenses were $29.1 million, compared to $43.4 million for the same period last year. The decrease in research and development expenses is primarily due to cost savings from our recent restructuring and decreasing external clinical development expenses related to the elagolix program. Personnel costs decreased in the first nine months of 2009 by $3.0 million compared with the first nine months of 2008 and
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... Oct. 16, 2014 Eight finalists, all representing ... to present their proposals for a chance to compete ... Sheikh Zayed Institute Second Annual Pediatric Surgical Innovation ... on Friday, Oct. 24, 2014. Selected ... across the US and internationally, the finalists are: ...
(Date:10/16/2014)... , Oct. 16, 2014   NuVascular ... process to create new medical devices that help ... Inc., the company uses cutting-edge nanotechnology that would ... kidney diseases.  The platform technology ... result of $6.6 million in funding obtained from ...
(Date:10/16/2014)... -- Ninety percent of children and adults with acute ... failed to respond to standard therapies went into remission ... at the Perelman School of Medicine at the University ... New England Journal of Medicine . ... presented at the American Society of Hematology,s annual meeting ...
Breaking Medicine Technology:Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Stephen T. Greenberg, ... been nominated for the 10th consecutive year as one of ... Dr. Greenberg was also been nominated as the best provider ... also nominated as best Day Spa and best Laser Treatment ... December 14th and readers can vote for the contest once ...
(Date:10/19/2014)... OCTOBER 20, 2014 – The U.S. Government has ... treat Alzheimer,s disease by 2025. However, a workgroup ... the research milestones in the U.S. Government,s National ... in scope, increased in scale, and adequately funded ... series of proposals by the workgroup to enlarge ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 19, 2014 ... in demand for proton therapy despite the high-cost structure ... resulting in market growth. , Analysts forecast the Global ... CAGR of 9.50 percent over the period 2013-2018. According ... this market is the technological advances in medical diagnostics ...
Breaking Medicine News(10 mins):Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4
... Offers a Simple Guide to Organizing Matters of Life ... are not organized with,medical information and life documents to ... Yorong in Lifetime Medical Organizer: A Simple,Guide to Organizing ... (published by AuthorHouse), the new book she wrote with,Richard ...
... Eight Alternatives to Exercise-Induced Asthma, INDIANAPOLIS, May ... chest pains while engaged in physical,activity, the default ... from,exercise-induced asthma (EIA). However, there are several other,explanations ... left untreated. A featured science session at the ...
... 10-K Extension ... ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires and ... to complete and file its fiscal 2008 Form,10-K with the Securities ...
... Water Beverage Presents Exercise Hydration Without the ... ... A new study presented at the,American College of Sports Medicine Annual ... beverage,developed by researchers for Scientific Food Solutions, LLC, for active,persons hydrates ...
... Paul Sierzenski, MD, RDMS, of Christiana Care Health System, ... care workers with immediate access to patient medical records ... that using radiofrequency devices that electronically contain a persons ... aid and reduce medical charges, two often incompatible goals. ...
... a new study, knowledge of potentially toxic household substances ... The results show that less than one-third of primary ... correctly estimate the toxicity of household poisons. The study ... Medicines 2008 Annual Meeting. , Led by Rika N. ...
Cached Medicine News:Health News:Lifetime Medical Organizer 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 2Health News:Pediatric Wheezing: If Not Asthma, Then What is It? 3Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 3Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 2Health News:Zero-Calorie Aqua-Lyte(R) Hydrates as Well as Traditional Sports Drinks 3
... The total ergonomic solution and best ... Soft, feather touch action and ultra lightweight ... Stress-free tip ejection with long, lever tip ... identification , Accepts universal tips or for ...
... The Finnpipette BioControl ... innovative features as the ... universal handle fits allseven ... channel tip cone modules. ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
Medicine Products: